Glenmark Life IPO: Glenmark Life IPO kicks off: Here's what makes analysts bullish on the issue

Anand Rathi said Glenmark Life has leadership in select high-value non-commercialized APIs in chronic therapeutic areas. It said the has cost leadership, a strong balance sheet, a growing business, and a high return on net worth (RoNW) of 46.71 per per cent. Add to that are reasonable valuations, which the brokerage said made it suggest a 'subscribe' on the issue.
Geojit Financial Services called the IPO fairly priced and suggested a 'Subscribe' for a long-term basis, considering Glenmark's strong focus on research and development (R&D), its expansion plans, the growth opportunity ahead in CDMO (contract development and manufacturing operations) services and expanding of complex API portfolio.

Related Keywords

China ,Anand Rathi ,Siddhant Khandekar ,Astha Jain ,Glenmark Life Sciences ,Geojit Financial Services ,Laurus Labs ,Shilpa Medicare ,China Plus One ,Glenmark Life ,Financial Services ,Hem Securities ,சீனா ,ஆனந்த் ரதி ,சித்தாந்த் கண்டெகர் ,ஆஸ்தா ஜெயின் ,க்ளேண்மர்க் வாழ்க்கை அறிவியல் ,ஜியோஜித் நிதி சேவைகள் ,லாரஸ் ஆய்வகங்கள் ,ஷில்பா மருத்துவ ,சீனா ப்லஸ் ஒன்று ,க்ளேண்மர்க் வாழ்க்கை ,நிதி சேவைகள் ,ஹேம் பத்திரங்கள் ,